Study design and participants
TNBC, breast cancer
BREAST CANCER
This open-label, multicenter, phase II clinical study evaluated the efficacy and safety of pamiparib as a single-agent therapy for patients with locally advanced or metastatic TNBC or HR+/HER2− breast cancer, harboring gPatients were recruited from 25 sites across China. Eligible patients were adults (≥ 18 years of age) with histologically or cytologically confirmed, locally advanced or metastatic HER2− breast cancer (TNBC or HR+/HER2− breast cancer) with deleterious or suspected deleterious gThe protocol was approved by the relevant Institutional Review Board/Independent Ethics Committee for each study site. This study was carried out in accordance with the International Conference on Harmonization, Good Clinical Practice Guideline, the principles of the Declaration of Helsinki, and local laws and regulations. All patients provided written informed consent before participation in the study.